Business Wire

Omeros Announces Update on Statistical Analysis of Narsoplimab Pivotal Trial Primary Endpoint

Narsoplimab-treated patients had an over 2-fold reduction (hazard ratio = 0.42 [95% confidence interval: 0.21, 0.83]) to an over 4-fold reduction (hazard ratio = 0.24 [95% confidence interval: 0.13, 0 ...
Healio

UBX1325 fails to meet primary analysis endpoint despite vision gains in DME

Please provide your email address to receive an email when new articles are posted on . UBX1325 did not meet statistical noninferiority to aflibercept on the average of weeks 20 and 24. Patients ...
Seeking Alpha

Jyong Biotech Announces Completion of Primary Endpoint Statistical Analysis for Phase II Clinical Trial of MCS-8 With Positive Outcomes

New Taipei City, Taiwan, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (MENS) (the “Company” or “Jyong Biotech”), a science-driven biotechnology company based in Taiwan committed to developing ...
Morningstar

Hungary Approves Trial Expansion as HT-001 Meets Primary Endpoint in Interim Analysis with Patients Reaching ARIGA ≤1 by Week Six

Over 65% of Patients Reported Reduced Pain and Itching; Zero Disruptions to EGFR Cancer Therapy with ~99% Lower Systemic Exposure NEW YORK, April 1, 2026 /PRNewswire/ -- Hoth Therapeutics, Inc.